The dollars were small but the trend was mighty. Such was the consensus of analysts on the first full quarter results for Acadia Pharmaceuticals Inc. following the launch of Nuplazid (pimavanserin) on May 31 to treat hallucinations and delusions associated with Parkinson's disease psychosis (PDP).